Nifuratel
Based on 3 publication(s) in Google Scholar
Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.93%
- CAS No.: 4936-47-4
- Formule: C10H11N3O5S
- Masse moléculaire:285.28
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
Kinase Inhibitor Library
HY-L009
-
Stem Cell Signaling Compound Library
HY-L017
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Covalent Screening Library
HY-L036
-
Differentiation Inducing Compound Library
HY-L038
-
Antifungal Compound Library
HY-L048
-
Antibacterial Compound Library
HY-L049
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Antiparasitic Compound library
HY-L082
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Cancer Stem Cells Compound Library
HY-L135
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
-
FDA Kinase Inhibitor Library
HY-L230
Publications Citing Use of MedChemExpress (MCE) Nifuratel
MoreVoir tous les produits spécifiques à Isoform Parasite
MoreVoir tous les produits spécifiques à Isoform Antibiotic
MoreVoir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Nifuratel kills all Salmonella in RAW264.7 cells at 25 µM. Nifuratel kills all Salmonella in mouse J774.1 cells, avian HD11 cells, and human Hela cells at 50 µM, 100 µM, and 100 µM, respectively[4]. Nifuratel (0-100 µM; 15 h) completely inhibits the growth of SE C50041 strain in broth at a concentration of 100 µM[4]. Nifuratel (10-300 µM; 24 h) dose-dependently reduces colony formation in SGC7901 and BGC-823 cell lines with IC50 values of 169.7 µM and 133.7 µM[5]. Nifuratel (75-300 µM; 24 h) blocks IL-6-induced activation of the STAT3 signaling pathway in SGC-7901 and BGC-823 cell lines[5]. Nifuratel inhibits antigen-induced degranulation in both RBL-2H3 cells and BMMCs in a concentration-dependent manner, with IC50 values of 0.34 µM and 0.9 µM[6]. Nifuratel (0-3 µM; 30 min) dose-dependently inhibits the secretion of histamine from antigen-stimulated mast cells and the release of inflammatory factors TNF-α and IL-4 in antigen-stimulated RBL-2H3 cells, with IC50 values of approximately 0.48 and 0.75 µM[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SGC7901 and BGC-823 gastric cancer cell lines
-
Concentration:75、100 and 300 µM
-
Incubation Time:24 h
-
Result:Induced the arrest of gastric cancer cells in the G2/M phase of the cell cycle.
-
Cell Line:SGC7901 and BGC-823 gastric cancer cell lines
-
Concentration:75、100 and 300 µM
-
Incubation Time:24 h
-
Result:Increased the expression of pro-apoptotic protein Bax and decreased the level of anti-apoptotic protein Bcl-2 in a dose-dependent manner. Reduced phosphorylated STAT3 (P-STAT3) protein levels in SGC-7901 and BGC-823 cell lines at a dose of 300 μM.
-
Cell Line:Antigen-stimulated RBL-2H3 cells
-
Concentration:0、0.3、1、3 µM
-
Incubation Time:30 min
-
Result:Inhibited the phosphorylation of Akt, ERK1/2, JNK and p38 in a concentration-dependent manner. Almost completely inhibited Syk and Syk-mediated signaling pathways at 3 μM concentration.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:IgE-dependent PCA mouse model[6]
-
Dosage:10、30 and 100 mg/kg
-
Administration:Oral gavage (p.o.); IgE (50 ng) was injected subcutaneously into the ear of mice and then orally the next day.
-
Result:Reduced mast cell degranulation in a dose-dependent manner in the ear tissue of the IgE-dependent PCA mouse model.
Chemical Information
-
CAS No. 4936-47-4
-
Appearance Solid
-
Masse moléculaire 285.28
-
Formule C10H11N3O5S
-
Color Light yellow to yellow
-
SMILES
O=C1OC(CSC)CN1/N=C/C2=CC=C([N+]([O-])=O)O2
-
Synonyms
NF 113; SAP 113; Methylmercadone
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis. [Abstract]2023 Jan 13;24(2):1635. PMID: 36675150 -
ACS Infect Dis
Ex Vivo Phenotypic Screening of Two Small Repurposing Drug Collections Identifies Nifuratel as a Potential New Treatment against Visceral and Cutaneous Leishmaniasis. [Abstract]2021 Aug 13;7(8):2390-2401. PMID: 34114790 -
Solvant et solubilité
DMSO : 50 mg/mL (175.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Polatti F. Bacterial vaginosis, Atopobium vaginae and nifuratel. Curr Clin Pharmacol. 2012 Feb 1;7(1):36-40. [Content Brief]
[2]. Nijevitch AA, et al. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy withnifuratel to furazolidone. Aliment Pharmacol Ther. 2005 Nov 1;22(9):881-7. [Content Brief]
[3]. Nijevitch AA, et al. Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children. Helicobacter. 2007 Apr;12(2):132-5. [Content Brief]
[4]. Xie T, et al. Nifuratel reduces Salmonella survival in macrophages by extracellular and intracellular antibacterial activity[J]. Microbiology Spectrum, 2023, 11(5): e05147-22. [Content Brief]
[5]. Zheng H, et al. Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells[J]. Cancer management and research, 2017: 565-572. [Content Brief]
[6]. Lee J E, et al. Drug repositioning of anti-microbial agent nifuratel to treat mast cell-mediated allergic responses[J]. International Journal of Immunopathology and Pharmacology, 2023, 37: 03946320231202349. [Content Brief]
[7]. Mendling W, et al. Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections[J]. Arzneimittelforschung, 2002, 52(01): 8-13. [Content Brief]
[8]. Tynan A P, et al. Nifuratel in urinary infections[J]. British Journal of Urology, 1969, 41(3): 271-279. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5053 mL | 17.5266 mL | 35.0533 mL | 87.6332 mL |
| 5 mM | 0.7011 mL | 3.5053 mL | 7.0107 mL | 17.5266 mL | |
| 10 mM | 0.3505 mL | 1.7527 mL | 3.5053 mL | 8.7633 mL | |
| 15 mM | 0.2337 mL | 1.1684 mL | 2.3369 mL | 5.8422 mL | |
| 20 mM | 0.1753 mL | 0.8763 mL | 1.7527 mL | 4.3817 mL | |
| 25 mM | 0.1402 mL | 0.7011 mL | 1.4021 mL | 3.5053 mL | |
| 30 mM | 0.1168 mL | 0.5842 mL | 1.1684 mL | 2.9211 mL | |
| 40 mM | 0.0876 mL | 0.4382 mL | 0.8763 mL | 2.1908 mL | |
| 50 mM | 0.0701 mL | 0.3505 mL | 0.7011 mL | 1.7527 mL | |
| 60 mM | 0.0584 mL | 0.2921 mL | 0.5842 mL | 1.4606 mL | |
| 80 mM | 0.0438 mL | 0.2191 mL | 0.4382 mL | 1.0954 mL | |
| 100 mM | 0.0351 mL | 0.1753 mL | 0.3505 mL | 0.8763 mL |
Nifuratel Related Classifications
HY-A0059 Related Classifications
Powered by Bioz